NCT06691308View on ClinicalTrials.gov

WL276 CAR-T Cell Therapy for CD276 Positive Recurrent or Progressive Glioblastoma Patients

EARLY_PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

November 12, 2024

Primary Completion Date

May 31, 2027

Study Completion Date

May 31, 2027

Conditions
Recurrent or Progressive Glioblastoma
Interventions
COMBINATION_PRODUCT

WL276 CAR-T cells

This study intends to include 6 subjects, with 3 subjects receiving 5 \* 10 \^ 6 CAR-T Cells and 3 subjects receiving 1 \* 10 \^ 7 CAR-T Cells at different doses

All Listed Sponsors
lead

Beijing Immunochina Medical Science & Technology Co., Ltd.

INDUSTRY

NCT06691308 - WL276 CAR-T Cell Therapy for CD276 Positive Recurrent or Progressive Glioblastoma Patients | Biotech Hunter | Biotech Hunter